11/25
07:30 am
vstm
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
Medium
Report
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
11/20
06:03 am
vstm
Verastem (NASDAQ:VSTM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Verastem (NASDAQ:VSTM) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/14
12:41 am
vstm
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
11/5
07:30 am
vstm
Verastem Oncology to Present at Upcoming Investor Conferences
Low
Report
Verastem Oncology to Present at Upcoming Investor Conferences
11/4
10:22 am
vstm
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/4
07:30 am
vstm
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
High
Report
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
10/31
07:16 am
vstm
Verastem (NASDAQ:VSTM) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
Verastem (NASDAQ:VSTM) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
10/29
10:07 am
vstm
Verastem (NASDAQ:VSTM) was given a new $15.00 price target on by analysts at Mizuho.
Low
Report
Verastem (NASDAQ:VSTM) was given a new $15.00 price target on by analysts at Mizuho.
10/25
11:32 pm
vstm
Can Verastem's (VSTM) Early KRAS Results Redefine Its Position in Oncology Innovation? [Yahoo! Finance]
Low
Report
Can Verastem's (VSTM) Early KRAS Results Redefine Its Position in Oncology Innovation? [Yahoo! Finance]
10/23
04:01 pm
vstm
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
Low
Report
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
10/23
07:30 am
vstm
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
Low
Report
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
10/22
12:24 pm
vstm
Verastem (NASDAQ:VSTM) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Verastem (NASDAQ:VSTM) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
10/21
02:12 pm
vstm
Verastem (NASDAQ:VSTM) was given a new $14.00 price target on by analysts at Mizuho.
Low
Report
Verastem (NASDAQ:VSTM) was given a new $14.00 price target on by analysts at Mizuho.
10/21
08:45 am
vstm
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/20
01:05 pm
vstm
Verastem (NASDAQ:VSTM) was given a new $13.00 price target on by analysts at Royal Bank Of Canada.
Medium
Report
Verastem (NASDAQ:VSTM) was given a new $13.00 price target on by analysts at Royal Bank Of Canada.
10/19
04:22 am
vstm
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma [Yahoo! Finance]
High
Report
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma [Yahoo! Finance]
10/19
04:15 am
vstm
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
High
Report
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
10/16
09:33 am
vstm
Verastem (NASDAQ:VSTM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Verastem (NASDAQ:VSTM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
10/7
11:59 pm
vstm
Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) [Seeking Alpha]
Low
Report
Verastem: Navigating Critical Steps In Commercialization And Development (Downgrade) [Seeking Alpha]
10/7
07:30 am
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/21
03:21 am
vstm
Low
Report
9/13
01:06 am
vstm
Low
Report
9/9
08:07 am
vstm
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $20.00 price target on the stock.
Low
Report
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $20.00 price target on the stock.